Treatment of patients with ovarian carcinoma with pegylated liposomal doxorubicin: Analysis of toxicities and predictors of outcome

Cancer

Volumn 91, Issue 1, 2001, Pages 90-100

  Safra, Tamar ^a,e   Groshen, Susan ^b   Jeffers, Susan ^c   Tsao Wei, Denice D ^a   Zhou, Linyun ^a   Muderspach, Laila ^d   Roman, Lynda ^d   Paul Morrow, C ^d   Burnett, Alexander ^d   Muggia, Franco M ^d  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c RUSH UNIVERSITY MEDICAL CENTER   (United States)

^d NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e NEW YORK UNIVERSITY   (United States)

Author keywords

Doxorubicin; Liposomal; Multivariate analysis; Ovarian carcinoma; Pegylated

Indexed keywords

CISPLATIN; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ETOPOFOS; GEMCITABINE; IRINOTECAN; PACLITAXEL; TOPOTECAN;

ADULT; AGED; ARTICLE; BONE MARROW TOXICITY; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; DRUG EFFICACY; DRUG RESPONSE; FATIGUE; FEMALE; FOOD POISONING; HEMOGLOBIN DETERMINATION; HUMAN; INFECTION; MAJOR CLINICAL STUDY; NEUTROPENIA; OVARY CARCINOMA; PAIN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; SKIN TOXICITY; STOMATITIS; TREATMENT OUTCOME; TUMOR VOLUME;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CARCINOMA; DOXORUBICIN; FEMALE; HEALTH STATUS; HEMOGLOBINS; HUMANS; LIPOSOMES; MIDDLE AGED; NEOPLASM STAGING; OVARIAN NEOPLASMS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0035165412     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-0142(20010101)91:1<90::AID-CNCR12>3.0.CO;2-A     Document Type: Article

References (28)

1. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with Stage III and Stage IV ovarian cancer
2. Prognostic factors in salvage therapy of ovarian cancer
3. Predictors of response to subsequent chemotherapy in platinum pretreated ovarian cancer. A multivariate analysis of 704 patients
4. Liposomal doxorubicin: Antitumor activity and unique toxicities during two complementary Phase I studies
5. Phase II study of liposomal doxorubicin in refractory ovarian cancer: Antitumor activity and toxicity modification by liposomal encapsulation
6. Pegylated liposomal doxorubicin: Antitumor activity in epithelial ovarian cancer or cancers of peritoneal origin
7. Therapy of human ovarian carcinoma xenografts using doxorubicin encapsulated in sterically stabilized liposomes
8. Comparative study of the antitumor activity of free doxorubicin and polyethylene glycol-coated liposomal doxorubicin in a mouse lymphoma model
9. Efficacy of pegylated-liposomal doxorubicin in the treatment of AIDS-related Kaposi's sarcoma after failure of standard chemotherapy
10. Cyclophosphamide, doxorubicin, and cisplatin chemotherapy for ovarian carcinoma. A meta-analysis
11. Meta-analysis of cisplatin, doxorubicin, and cyclophosphamide versus cisplatin and cyclophosphamide chemotherapy in ovarian carcinoma
12. Impact of doxorubicin on survival in advanced ovarian cancer
13. Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria
14. Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125
15. Responses to salvage chemotherapy in ovarian cancer: A critical need for precise definitions of the treated population
16. Contribution to the discussion on the paper by R. Peto and J. Peto, "Asymptotically efficient rank invariant procedures."
17. A comparison of two simple hazard ratio estimators based on the logrank test
18. Chi-square tests with one degree of freedom: Extensions of the Mantel-Haenszel procedure
19. Doxil (D) in platinum-refractory epithelial ovarian cancer (EOC): Results from three consecutive Phase I/II studies
20. Doxil® (doxorubicin HCl liposome injection) in the treatment of patients with refractory advanced epithelial carcinoma
21. Interim analysis of a Phase III randomized trial of Doxil/Caelyx (D) versus topotecan (T) in the treatment of patients with relapsed ovarian cancer
22. High-dose chemotherapy with autologous transplantation for persistent/relapsed ovarian cancer: A multivariate analysis of survival for 100 consecutively treated patients
23. Activity of anthracyclines in refractory ovarian cancer: Recent experience and review
24. First-line chemotherapy with epirubicin, paclitaxel, and carboplatin for advanced ovarian cancer: A Phase I/II study of the Arbeitsgemeinschaft Gynakologische Onkologie Ovarian Cancer Study Group
25. Phase I studies of Doxil combined with cisplatin: Efficacy in epithelial ovarian and fallopian tube cancers
26. Continuous infusion topotecan (TP-CI) and Doxil (Dx): A Phase I study of dual topoisomerase inhibition